Current Treatment Options in Neurology

, Volume 15, Issue 4, pp 519–528

New Treatment Options for Lennox-Gastaut Syndrome


DOI: 10.1007/s11940-013-0223-z

Cite this article as:
Lemmon, M.E. & Kossoff, E.H. Curr Treat Options Neurol (2013) 15: 519. doi:10.1007/s11940-013-0223-z

Opinion statement

Lennox-Gastaut syndrome (LGS) is one of the most difficult epilepsy syndromes to treat, and many children are refractory to standard treatment regimens. Valproic acid, topiramate, and lamotrigine are considered first-line therapies. Newer agents, including clobazam and rufinamide, are promising additions to the current treatment options. The ketogenic diet and vagus nerve stimulation are important adjuncts, with increasing evidence to support their use. Corpus callosotomy should be considered in refractory cases. Finally, focal resective surgery should be considered in patients with lesional disease, although for most patients with LGS this is unlikely to be the case.


Lennox-Gastaut syndrome LGS Epilepsy Treatment Clobazam Rufinamide Topiramate Lamotrigine Levetiracetam Valproic acid Zonisamide Felbamate Ketogenic diet Vagus nerve stimulator Corpus callostomy 

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of NeurologyThe Johns Hopkins HospitalBaltimoreUSA

Personalised recommendations